Ulcerative Colitis: The Complete Guide to Medical Management

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Start Reading Now:

• Chapter 1: The Natural History of Inflammatory Bowel Disease
• Chapter 2: Clinical Research in Inflammatory Bowel Disease
• Chapter 3: The Role of the FDA in Drug Development in Inflammatory Bowel Disease
• Chapter 4: Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease
• Chapter 5: Pediatric Considerations in Medical Therapy in Patients with Inflammatory Bowel Disease
• Chapter 6: The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease
• Chapter 7: Disease Modifiers in Inflammatory Bowel Disease
• Chapter 8: Fertility and Pregnancy in Inflammatory Bowel Disease
• Chapter 9: Diversion Colitis
• Chapter 10: Medication Adherence in Inflammatory Bowel Disease
• Chapter 11: General Principles of Medical Therapy of Ulcerative Colitis
• Chapter 12: Assessment of Disease Activity in Ulcerative Colitis
• Chapter 13: Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis
• Chapter 14: Current and Future Topical Mesalamine Derivatives in Ulcerative Colitis
• Chapter 15: Antibiotics in Ulcerative Colitis
• Chapter 16: Oral and Parenteral Corticosteroids in Ulcerative Colitis
• Chapter 17: Topical Corticosteroid Use in Ulcerative Colitis
• Chapter 18: 6-Mercaptopurine and Azathioprine Use in Ulcerative Colitis
• Chapter 19: Azathioprine Metabolism in Inflammatory Bowel Disease
• Chapter 20: Methotrexate in the Treatment of Ulcerative Colitis
• Chapter 21: Calcineurin Inhibitors (Cyclosporine, Tacrolimus, Sirolimus) and Mycophenolate Mofetil Use in Ulcerative Colitis
• Chapter 22: Infliximab Use in Ulcerative Colitis
• Chapter 23: Other Tumor Necrosis Factor-Alpha Antagonists in Ulcerative Colitis
• Chapter 24: Novel Biological Agents for the Treatment of Ulcerative Colitis
• Chapter 25: Novel Nonbiological Therapy for Ulcerative Colitis
• Chapter 26: Medical Management of Severe Ulcerative Colitis
• Chapter 27: Medical Management of Toxic Megacolon in the Patient with Ulcerative Colitis
• Chapter 28: Medical Management of Ulcerative Proctitis
• Chapter 29: Medical Therapy of Left-Sided Ulcerative Colitis
• Chapter 30: Management of Refractory Ulcerative Colitis
• Chapter 31: Pseudointractability of Inflammatory Bowel Disease
• Chapter 32: Medical Management of Extraintestinal Manifestations of Ulcerative Colitis
• Chapter 33: Nicotine and Inflammatory Bowel Disease
• Chapter 34: Management of Steroid-Refractory and Steroid-Dependent Severe Ulcerative Colitis
• Chapter 35: Prebiotics and Probiotics of Ulcerative Colitis
• Chapter 36: Management of Acute and Chronic Pouchitis
• Chapter 37: Dietary Manipulations
• Chapter 38: Parenteral Nutrition Use in Ulcerative Colitis
• Chapter 39: Maintenance of Remission in Ulcerative Colitis

Buy Book

• $115.95
• ISBN 10 1-55642-945-2
• ISBN 13 978-1-55642-945-3
• 512 pp Hard Cover
• Pub. Date: 2011
• Order# 79453